Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion

Background Prior studies suggest that renin-angiotensin-aldosterone system (RAAS) inhibitors decrease parathyroid hormone (PTH) secretion. Objective To evaluate the effect of angiotensin-converting enzyme inhibitors (ACEi) on serum PTH in participants with and without primary hyperparathyroidism (P-HPT). Methods An open-label, single-arm, pilot study whereby participants with and without P-HPT had PTH were evaluated before and after 1 week of maximally tolerated lisinopril therapy. Results A total of 12 participants with, and 15 participants without, P-HPT successfully completed the protocol. Following 1 week of lisinopril, participants with P-HPT had a decrease in systolic blood pressure (SBP) (−6.4 mmHg, P < 0.01), an increase in plasma renin activity (PRA) (+1.50 ng/mL/h, P = 0.06), and a decrease in PTH (79.5 (21.6) to 70.9 (19.6) pg/mL, ∆ = −8.6 pg/mL, P = 0.049); however, serum and urine calcium did not change. In contrast, although 1 week of lisinopril significantly decreased SBP and increased PRA among participants without P-HPT, there were no changes in PTH or calcium. Conclusion In this short pilot investigation, 1 week of maximally titrated ACEi did not impact PTH in participants without P-HPT, but resulted in a modest and marginally significant reduction of PTH but not calcium, among participants with P-HPT. This trial is registered with ClinicalTrials.gov NCT01691781.

• Publication year

  2017

• Venue

  International Journal of Endocrinology

• Publication date

  2017-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2017/4138783PMID 28808443PMCID 5541811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial

  2016cited by this paper
• Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.

  2015influential reference
• Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk.

  2015cited by this paper
• Human Interventions to Characterize Novel Relationships Between the Renin–Angiotensin–Aldosterone System and Parathyroid Hormone

  2014influential reference
• Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.

  2014cited by this paper
• Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis).

  2014cited by this paper
• Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism.

  2014cited by this paper
• Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy: results of a prospective case control study.

  2013cited by this paper
• Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study.

  2013cited by this paper
• Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik.

  2013cited by this paper
• Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies.

  2013cited by this paper
• Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma

  2012cited by this paper
• Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism

  2012cited by this paper
• Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study.

  2012cited by this paper
• The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure.

  2011cited by this paper
• Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage?

  2011cited by this paper
• Primary Hyperparathyroidism With Concurrent Primary Aldosteronism

  2011cited by this paper
• Clinical practice. Primary hyperparathyroidism.

  2011cited by this paper
• Long-Term Effects of Parathyroidectomy on Hypertension Prevalence and Circadian Blood Pressure Profile in Primary Hyperparathyroidism

  2010cited by this paper
• Progression of cardiovascular damage: the role of renin-angiotensin system blockade.

  2010cited by this paper
• Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography.

  2010cited by this paper
• Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).

  2010cited by this paper
• Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.

  2009cited by this paper
• Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism.

  2009cited by this paper
• Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.

  2006cited by this paper
• Primary hyperparathyroidism and heart disease--a review.

  2004cited by this paper
• Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.

  2002cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism.

  1998cited by this paper
• Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures

  1997cited by this paper
• Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.

  1995cited by this paper
• Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension

  1992cited by this paper
• Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism

  1987cited by this paper
• Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.

  1981cited by this paper
• Hypertension and Hyperparathyroidism

  1972cited by this paper

• Saline Suppression Testing-Induced Hypocalcemia and Implications for Clinical Interpretations.

  2024cites this paper
• Chronic administration of Musa acuminata Colla (BANANA) to Wistar albino rats induces hyperkalemia

  2024cites this paper
• The Relationship between Renin–Angiotensin–Aldosterone System (RAAS) Activity, Osteoporosis and Estrogen Deficiency in Type 2 Diabetes

  2023cites this paper
• Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo‐controlled randomized trial

  2022cites this paper
• [Dynamic changes of renin-angiotensin-aldosterone system parameters after surgery of primary hyperparathyroidism].

  2020cites this paper
• Physical Activity-Dependent Regulation of Parathyroid Hormone and Calcium-Phosphorous Metabolism

  2020cites this paper
• The Interplay Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone

  2020cites this paper
• PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy.

  2019cites this paper
• Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo‐controlled trial

  2018cites this paper
• Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.

  2017cites this paper